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Abstract 
Background: CpG Island Methylator Phenotype (CIMP) has been identified as a 
distinct molecular subtype of gastric cancer, yet associations with survival are 
conflicting. A meta-analysis was performed to estimate CIMP’s prognostic 
significance.  
 
Methods: A systematic review of Embase, Medline, PubMed, PubMed Central and 
Cochrane databases on studies related to the association between CpG Island 
Methylator Phenotype and survival in patients undergoing potentially curative 
resection for gastric cancer was done. 
 
Results: A total of 967 patients from 10 studies were included, and the median rate of 
tumour CIMP-H (high) was 40.9% (range 5.3 - 62.7%). Pooled analysis suggested 
that specimens exhibiting CIMP-H were associated with poorer 5-year survival (OR 
1.49, 95% CI 1.11 - 2.01, p<0.05). Significant heterogeneity was observed between 
studies (I2 = 88%, p<0.001). Sub-analysis related to poor (5 studies) or improved 
outcomes (5 studies), revealed that CIMP was associated with both poor (OR 8.15, 
95% CI 4.65 - 14.28, p<0.05, study heterogeneity I2 = 52%, p=0.08) and improved 
survival (OR 0.42, 95% CI 0.27 - 0.65, p<0.05, study heterogeneity I2 = 0%, 
p=0.960).  
 
Conclusion: There was significant heterogeneity in the gene panels used to identify 
CIMP, which may explain the survival differences. 
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Introduction 
Gastric cancer is the second commonest cause of cancer related death 
worldwide accounting for some 740,000 deaths annually1. Surgery remains the only 
treatment modality with curative potential but some 40% of patients develop 
recurrence and die of their disease. Response rates to chemotherapy are poor, and 
prescribing adjuvant chemotherapy to all patients has no evidence base and is not 
recommended. Hence, one of the prime challenges is to identify biomarkers that may 
improve prognostic modeling, independent of the current AJCC TNM staging system, 
and which may promote new therapeutic targets. 
 The molecular mechanism underlying gastric cancer carcinogenesis remains 
unclear, however, genomic and epigenetic changes are important causes of activation 
of oncogenes and silencing of tumour suppression genes. Epigenetic silencing through 
hypermethylation of CpG islands of the genes promoter region plays an important 
role in silencing tumour related genes2. There is conflicting evidence reporting CpG 
Island Methylator Phenotype (CIMP) with survival3-4. The relatively small sample 
sizes reporting CIMP positivity with survival makes interpreting the true prognostic 
influence of this biomarker difficult. A possible solution is to perform a meta-analysis 
of published data. Unfortunately, the meta-analysis performed by Zong and Seto 
contained only 2 studies reporting the prognostic value of CIMP5. Therefore, the aim 
of this study was to perform a systematic review and meta-analysis of the prognostic 
value of CIMP status in gastric cancer using overall survival as the time-to-event 
endpoint. 
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Methods 
Search protocol.  
Original studies were searched for those that documented patients with surgically 
resected primary gastric adenocarcinoma, where the specimens were assessed for the 
presence of CpG Island Methylator phenotype (CIMP). The outcome measure chosen 
was 5-year overall survival. Embase, Medline, PubMed, PubMed Central and 
Cochrane databases were searched using the following Boolean search term: CpG 
Island Methylator Phenotype AND (cancer OR carcinoma OR adenocarcinoma OR 
tumor OR tumour) AND (Gastric OR stomach) for articles published up to March 
2017. All search results were combined in a reference manager database (Endnote) 
and duplicates removed. A grey search of reference lists of included studies was also 
undertaken.  
 
Study selection  
All types of original scientific reports were considered. Reviews and book chapters 
were excluded, as were texts written in languages other than English, and reports 
including survival analysis or patients who did not undergo surgery with curative 
intent. Only studies related to the association between CpG Island Methylator 
Phenotype and survival in patients undergoing potentially curative resection for 
gastric cancer were therefore included.  
 
Data extraction  
Two independent reviewers applied the inclusion criteria to study abstracts and 
selected full papers for data analysis. Data from full text papers were extracted by a 
single reviewer, with 50% undergoing independent review.  Discrepancies were 
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verified by consensus. If multiple publications reported results in the same population, 
the most comprehensive data were chosen. For each study, baseline data (author, 
institution, country, study period, total number of patients, gender, TNM stage, CIMP 
definition and methodology) were extracted. The number of patients exhibiting 
CIMP, and 5-year overall survival death rates were obtained where available. 
Outcomes were described as odds ratios with 95% confidence intervals. Where these 
were not reported, the methods described by Parmar and Rogers were used to extract 
data from Kaplan–Meier curves, or percentage survival6-7. Authors were contacted if 
data was not presented in a useable form.  
 
Definition of CpG Island Methylator Phenotype  
No consensus on the most accurate method of assessing CIMP exists; with variation 
in the cut-off for gene promoter methylation and the number/type of genes studied. 
For this reason, the defined term was catalogued from each included paper and 
displayed in the results. For the analysis, CIMP was determined to be either present 
(positive) or absent (negative). Where CIMP was graded into groups (e.g., high (H) 
/low (L) /none (N)), the results for the low/none groups were combined (CIMP-
negative) and compared with the CIMP-H (CIMP-positive) group.  
 
Quality of studies.  
This meta-analysis was conducted in accordance with the preferred reporting items 
for systematic reviews and meta-analyses (PRISMA) guidelines. The quality of the 
studies was measured using the Newcastle–Ottawa Scale which assesses the 
methodological quality of non-randomised cohort studies for meta-analysis. The 
studies were judged by two independent assessors using a nine-point scale comprising 
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analysis on the selection of the study group, the comparability of cohorts and the 
ascertainment of outcome. Scores above 6 points were taken to denote studies of high 
methodological quality and were included in the meta-analysis.  
 
Meta-analysis of CIMP status, clinicopathological factors and survival 
Methylation of the promoter region of a gene results in epigenetic silencing and a 
subsequent loss of expression of the target protein. There are two possible 
explanations for potentially conflicting survival results; first, the observed prognostic 
association between CIMP status and survival is influenced by the choice of gene 
panel; second, the clinicopathological make-up of the cohort identifies different 
molecular subtypes of CIMP tumours. To test the first hypothesis, studies and genes 
were grouped by survival and oncogene/tumour suppressor genes (TSG). To test the 
second hypothesis, comparisons were made between the clinicopathological factors 
and the CIMP status of the meta-cohorts, when studies were dichotomised based on 
the reported survival observed. 
 
Statistical analysis  
All analyses were conducted with the RevMan statistical package (Review Manager 
(RevMan) Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2014). Heterogeneity between studies was tested using Cochran’s G 
test. The I2 statistic was calculated for an objective measure of heterogeneity. A fixed-
effects meta-analysis was performed in all cases, and where there was appreciable 
heterogeneity (I2 > 50% or chi-squared p-values<0.10), a random-effects model was 
used. Corresponding funnel plots of Ln standard error as a function of effect size were 
used to examine the effect of publication bias visually, and were statistically tested 
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using Eggers test. P-values >0.05 were indicative of no publication bias.  For meta-
analysis, Mantel–Haenszel Odds Ratios for CIMP status and 5-year death rate was 
extracted and described with 95% confidence intervals. Sensitivity analysis was 
performed to identify if any methodological features were indicative of heterogeneity 
among studies. Studies were excluded if they had poor methodological quality 
(Newcastle - Ottawa scores <7).  
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Results 
The electronic search of the literature yielded 110 potential studies. A grey search 
through cross-referencing did not yield any additional manuscripts. Of the 110 
studies, 96 were excluded based on the contents of the abstract (figure 1). Forty-four 
studies concerned non-gastric cancers, 4 looked at single gene methylations, and 46 
did not include survival information. Of the 14 studies undergoing full text 
evaluation, 4 did not include survival information and therefore 10 studies were 
retained for final analysis (table 1) 3-4, 8-15. The median quality score for studies was 9 
(range 8-9). All studies were retrospective cohort studies of one or regional 
institutions and therefore constitute level IV evidence. All studies reporting 
methylation of CpG Islands on promoter regions of genes were based on resected 
specimens.   
 The 10 studies contained 967 patients with a median sample size of 81 (range 
68 - 196). Only three studies contained more than 100 patients. Eight studies included 
patients with TNM stage I-IV disease with only Ayed-Guerfali and Liu et al including 
patients with stage I-III disease. The approximate median age of the studied patients 
was 60 years with most being male (range 59% - 82%). Nine studies gave no 
information on the use of chemotherapy with only An et al. reporting that neoadjuvant 
chemotherapy was not prescribed.   
 CpG Island methylation was quantified on a median of 5.5 genes (5 - 28). The 
range of genes used are shown in table 2. The CIMP categorisation thresholds varied 
however, and the most common groupings were a trichotomy of CIMP-N (normal), 
CIMP-L(low) and CIMP-H(high). The prevalence of CIMP-H ranged from 5.3% to 
62.7% with a median of 40.8%. Five studies reported an association between CIMP-H 
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and improved survival, four studies reported an association with poorer survival, and 
a single study reported no statistically significant association with survival (table 2).     
  
Meta-analysis of CIMP status, clinicopathological factors and survival 
For the purposes of pooled analysis, CIMP-H (CIMP positive) was compared 
with a combined grouping of CIMP-L and CIMP-N (CIMP negative). The pooled 
Odds Ratio for CIMP positive and death was 1.49 (95% Confidence Interval (CI) 1.11 
- 2.01). Significant study heterogeneity was noted χ2 = 75.66, 9 d.f., p < 0.001, I2 = 
88% (figure 2).  
Studies and genes were grouped related to survival and oncogene/tumour 
suppressor genes (TSG) respectively (supplementary table 1). Studies demonstrating 
an association between CIMP positivity and improved survival had gene panels 
consisting of TSGs and oncogenes. In the studies demonstrating an association 
between CIMP positivity and poor outcome, apart from Park et al, all of the studies 
included tumour suppressor genes predominantly in their gene panels. Comparisons 
were made between the clinicopathological factors and CIMP status of the meta-
cohorts when studies were dichotomised based on the reported survival. The only 
extractable data related to clinicopathological factors were gender and TNM stage, 
which were classified as early (stage I and II), or advanced (stage III and IV). The 
frequency of male patients in studies reporting improved survival was 66.7%, 
compared with 69.6% in studies reporting poor survival (p=0.440). The proportion of 
patients with advanced disease in studies reporting improved survival was 53.5%, 
compared with 68.0% in the studies reporting poor survival (p<0.001). The ratio of 
CIMP negativity to positivity was 2.3 in the poor survival cohort, and 2.1 in the 
improved survival cohort. Despite this, CIMP positivity was associated with advanced 
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TNM stage (p<0.001) in the poor survival cohort (supplementary table 2). The 
association between CIMP positivity and early stage in the improved survival cohort 
was not statistically significant (p=0.061, supplementary table 2). 
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Discussion 
This study found marked variability in the genes employed in the selection panel for 
determining CIMP status, with clear heterogeneity related to survival. Five studies 
showed associations with improved, and 4 studies associations with poor survival. 
The 5-year survival for CIMP positivity ranged from 68% in studies reporting 
improved survival, to 14.3% in those reporting poor survival. The causes of these 
observations were unclear, but likely reflect the make up of the individual patient 
cohorts and gene selection panel, as the poor survival meta-cohort had a higher 
proportion of advanced disease (53.5% vs. 68.0%, p<0.001), and was predominantly 
composed of tumour suppressor genes. The lack of a consensus regarding CIMP 
status methodology in gastric cancer makes translating this potential biomarker into 
clinical practice challenging.  
 Heterogeneity in the methodology for determining CIMP status was a major 
finding, with the number, type, and identity of genes employed in the selection panel 
different in every study. Such findings have also been report in colorectal cancer by 
Jia et al, who reported that in 16 studies the number of markers ranged from 5 to 15, 
and different critical values were used16. The prevalence of CIMP ranged from 6.4% 
to 48.5% in colorectal cancer, compared with 5.3% to 94.1% in gastric cancer. It is 
possible that methylation occurs in a number of CpG islands, which has little 
influence on the phenotype of the cancer, but it is unknown to what extent these 
methylated genes are passengers, rather than drivers, and composing the CIMP panel 
with cancer drivers may provide a better picture of CIMP’s pathogenesis and 
prognostic impact.   
 Meta-analysis of cohorts associating CIMP with poor outcomes revealed that 
CIMP was associated with a more advanced TNM stage, yet a meta-analysis of 
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cohorts associated with CIMP improved outcomes, revealed that CIMP positivity was 
associated with earlier TNM stage (supplementary table 2). The reason for this is 
unclear, but it emphasises the importance of using study cohorts that reflect the 
population being treated. Standardised biomarker reporting, including the cohort 
composition, adds to result reliability, which is particularly important given the 
variability in stage and survival observed between eastern and western populations. It 
is possible that cancers arising from these cohorts are phenotypically different but 
could only be evaluated once consensus regarding the optimum methodology has 
been agreed and validated. 
 The studies contained in this systematic review used 59 different genes across 
10 studies. This was not a comprehensive analysis of cancer related genes, with less 
than 1% of the genome studied. It is now becoming clearer that cancer related genes 
may be described as ‘drivers’ or ‘passengers’ depending on their influence on 
carcinogenesis, growth and metastasis. It possible that tumours with large numbers of 
methylated ‘passenger’ genes are identified as CIMP despite these ‘passenger’ genes 
having little influence on the final phenotype and subsequent prognosis. Epigenetic 
silencing of the hMLH1 gene, which leads to loss of the mismatch repair protein 
expression and the microsatellite instability (MSI) phenotype, has been associated 
with improved survival in both colorectal and gastric cancer 2, 12. Furthermore, in this 
systematic review, studies using hMLH1 in their gene panel were all associated with 
improved survival. In colorectal cancer the CIMP+/MSI+ phenotype is a recognised 
entity associated with improved survival. hMLH1 can be confidently identified as a 
cancer driver and therefore the CIMP+/hMLH1 subtype likely explains the observed 
improved survival in some of the CIMP studies, although it remains unclear why 
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CIMP was associated with poor survival in a subset of studies which deserves further 
evaluation.   
 The Cancer Genome Atlas Network identified 4 molecularly distinct subtypes 
of gastric cancer, based on Epstein-Barr virus (EBV), MSI, chromosomal instability 
(CIN) and genomic stability (GS)17. In particular, EBV and MSI gastric cancer were 
reported to be associated with hypermethylation of promoter regions of up to 526 
genes. Based on molecular associations, four cluster patterns of hypermethylation 
have been reported, with two attributed to EBV and MSI gastric cancer, but 
unfortunately, neither survival analysis, nor a defined classification for CIMP was 
given. Nevertheless, it is clear that even within a hypermethylation subgroup, there is 
heterogeneity, which is likely to exhibit different associations with survival. 
Therefore, the different gene panels employed in this systematic review may identify 
subtypes of CIMP, and consensus regarding methodology is desirable. 
CIMP’s value as a predictive biomarker to guide whether or not to prescribe 
neoadjuvant or adjuvant chemotherapy is uncertain. Shiovitz et al. reported that in 
patients with stage III colorectal cancer undergoing Fluorouracil/Leucovorin therapy, 
CIMP positivity was associated with poorer survival compared with CIMP negativity, 
consistent with chemotherapy resistance 18. The proportion of gastric cancer patients 
responding to neoadjuvant chemotherapy is reported to be in the order of 21%, and 
although performing CIMP analysis on diagnostic biopsies is possible, 19 this strategy 
might not be pragmatic, because of the variable amount of cancer genomic material 
available within any given biopsy, and any such approach would require validation. 
Nevertheless, CIMP is a promising biomarker for the management of patients with 
gastric cancer and further work to quantify and validate this technique to determine its 
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relationship with responses to contemporary chemotherapeutic algorithms may 
support its integration into clinical practice.   
 This study has a number of inherent limitations, in the main related to the 
spectrum of gene panel markers utilized for CIMP. Unfortunately, this is a common 
finding pervading CIMP studies, and other systematic reviews and meta-analyses in 
colorectal cancer16 and gastric cancer5 have accepted this relative limitation when 
performing pooled analyses. In contrast, the study has significant strength in that it is 
the first systematic review and meta-analysis of prognostic studies relating to CIMP 
in gastric cancer, and the studies included were methodologically sound with 
Newcastle-Ottawa scores of >7.  
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Table 1. Baseline data on included studies 
 
 
* The status of neoadjuvant +/- adjuvant chemotherapy was unknown apart from one 
study (An et al), where the patients did not receive neoadjuvant chemotherapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
First Author Study 
period 
Number 
of 
patients 
Age Gender AJCC  
stage 
Surgery Evidence 
level 
Newcastle-
Ottawa 
Score 
An8* 1986 - 
1998 
83 Data not 
given 
65% 
male 
I-IV Yes IV 9 
Ayed-
Guerfali9 
2000 - 
2008 
79 Mean  
57 years 
59% 
male 
I-III Yes IV 9 
Chang10 1996 - 
1998 
106 Median  
>60 years 
76% 
male 
I-IV Yes IV 9 
Chen11 2003 - 
2009 
120 Mean  
58 years 
67% 
male 
I-IV Yes IV 9 
He3 2000 - 
2006 
94 Median  
<60 years 
82% 
male 
I-IV Yes IV 8 
Ksiaa12 1998 - 
2002 
68 Mean  
61 years 
59% 
male 
I-IV Yes IV 8 
Kusano13 Data not 
given 
78 Mean  
65 years 
67% 
male 
I-IV Yes IV 8 
Liu14 2008 - 
2009 
75 Mean  
52 years 
71% 
male 
I-III Yes IV 8 
Park4 2002 - 
2003 
196 Mean  
59 years 
68% 
male 
I-IV Yes IV 9 
Shigeyasu15 1998 - 
2004 
68 Median  
<70 years 
68% 
male 
I-IV Yes IV 9 
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Table 2. Baseline data on included studies 
 
First author CIMP markers CIMP cut-off 
value 
CIMP distribution Association with 
survival 
An8* p16, hMLH1, 
MINT1, MINT2, 
MINT25 and 
MINT31 
CIMP-H (> 50%)  
CIMP-L (< 50%)  
CIMP-N 
26 (31.3%) 
46 (55.4%) 
11 (13.3%) 
CIMP-H 
improved survival 
(p=0.040) 
Ayed-
Guerfali9 
RARb2, DAPK, 
RASSFIA, CDH1, 
p16INK4a 
CIMP-H ≥ 3 
CIMP-N < 3 
40 (50.6%) 
39 (49.4%) 
CIMP-H poorer 
survival  
(p=0.003) 
Chang10 LOX, HRASLS, 
FLNc, HAND1, TM, 
p14, p15, p16, p73, 
GPSTP1, MGMT, 
hMLH1, TIMP-3, E-
cadherin and DAPK.  
(Indicator genes - 
LOX, HRASLS, 
FLNc, HAND1 and 
TM) 
CIMP-H = 4-5  
CIMP-L = 1-3  
CIMP-N = 0 
40 (37.7%) 
41 (38.7%) 
25 (23.6%) 
CIMP-H 
improved survival  
(p=0.031) 
Chen11 ALX4, TMEFF2, 
CHCHD10, IGFBP3 
and NPR1 
CIMP-H = 4-5  
CIMP-L = 1-3  
CIMP-N = 0 
18 (15.0%) 
94 (78.3%) 
8 (6.7%) 
CIMP-H poorer 
survival  
(p<0.001) 
He3 p16, FHIT, CRBP1, 
WWOX and DLC-1 
CIMP-H = 4-5  
CIMP-L = 1-3  
CIMP-N = 0 
53 (56.4%) 
25 (26.6%) 
16 (17.0%) 
CIMP-H poorer 
survival  
(p=0.003) 
Ksiaa12 RASSFIA, APC, 
hMLH1, MGMT, 
GSTP1, p14, p16, 
DAPK, SHP1, RAR-
b2 and TIMP3 
CIMP-H ≥ 3 
CIMP-L = 1-2  
CIMP-N = 0  
41 (60.3%) 
23 (33.8%) 
4 (5.9%) 
CIMP-H 
improved survival  
(p=0.075) 
Kusano13 MINT1, MINT2, 
MINT12, MINT25, 
MINT32 
CIMP-H = 4-5  
CIMP-L = 1-3  
CIMP-N = 0 
19 (24.4%) 
39 (50.0%) 
20 (25.6%) 
CIMP-H 
improved survival  
(p=0.004) 
Liu14 APC, WIF-1, 
RUNx£, DLC-1, 
SFRP-1, DKK and E-
cad 
CIMP-H ≥ 3 
CIMP-N < 3 
47 (62.7%) 
28 (37.3%) 
No statistical 
difference (p > 
0.05) 
Park4 BCL2, BDNF, 
CACNA1G, 
CALCA, CHFR, 
CYP1B1, DLEC1, 
GRIN2B, RUNX3, 
SEZ6L, SFRP4, 
TERT, THBS1, 
TIMP3, TP73, 
TWIST1 
CIMP-H ≥14  
CIMP-L <14 
9 (5.3%) 
187 (94.7%) 
CIMP-H poor 
survival  
(p=0.012) 
Shigeyasu15 APC, CACNA1G, 
CHFR, COX2, 
DAPK, DCC, HPP1, 
MGMT-Mp region, 
MGMT-Eh region, 
MINT1, MINT2, 
MINT31, MLH1 5', 
CIMP-H ≥10  
CIMP-L <10 
30 (44.1%) 
38 (55.9%) 
CIMP-H 
improved survival  
(p=0.069) 
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Figure 1. Flowchart of literature selection 
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Figure 2. Association between CIMP positivity and overall survival (pooled analysis) 
 
 
 
 
 
 
 
 
 
